Data / Drug companies / AstraZeneca Pharmaceuticals LP
AstraZeneca Pharmaceuticals LP: 94 products in the FDA NDC directory, labeler code 0310
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
AstraZeneca Pharmaceuticals LP (labeler code 0310) lists 94 products in the FDA National Drug Code Directory, covering 27 finished drugs by generic name. By type: 68 prescription drugs, 16 drugs for further processing. Its main marketing category is new drug applications (NDA). The newest product started marketing on September 4, 2026.
The request: Watch AstraZeneca Pharmaceuticals LP (FDA labeler code 0310): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0310
- Products in commercial distribution
- 94
- Packages
- 134
- Finished drugs by generic name
- 27
- Prescription products
- 68
- Over the counter products
- 0
- Flagged as original packager
- 48 of 48 products that carry the flag
- Started marketing in the last 12 months
- 10
- Products with a marketing end date set
- 14
- Earliest marketing start
- October 1, 1997
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 56 | 59.6% |
| Drugs for further processing | 16 | 17% |
| Bulk ingredients | 10 | 10.6% |
| Biologics (BLA) | 10 | 10.6% |
| Authorized generics (NDA) | 2 | 2.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 68 | 72.3% |
| Drugs for further processing | 16 | 17% |
| Bulk ingredients | 10 | 10.6% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Quetiapine | 9 | 30 |
| Dapagliflozin and metformin hydrochloride | 5 | 10 |
| Selumetinib | 4 | 1 |
| Olaparib | 4 | 1 |
| Osimertinib | 4 | 1 |
| Rosuvastatin | 4 | 19 |
| Acalabrutinib | 3 | 1 |
| Benralizumab | 3 | 1 |
| Sodium zirconium cyclosilicate | 2 | 2 |
| Durvalumab | 2 | 1 |
| Dapagliflozin | 2 | 26 |
| Capivasertib | 2 | 1 |
| Tremelimumab | 2 | 1 |
| Exenatide | 2 | 2 |
| Eplontersen | 2 | 1 |
| Baxdrostat | 2 | 1 |
| Roflumilast | 2 | 17 |
| Pramlintide acetate | 2 | 1 |
| Budesonide, glycopyrrolate, and formoterol fumarate | 2 | 1 |
| Budesonide and formoterol fumarate dihydrate | 2 | 5 |
| Anifrolumab-fnia | 2 | 1 |
| Fulvestrant | 1 | 21 |
| Glycopyrrolate and formoterol fumarate | 1 | 1 |
| Camizestrant | 1 | 1 |
| Andexanet alfa | 1 | 1 |
| Albuterol sulfate and budesonide | 1 | 1 |
| Gefitinib | 1 | 5 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 31 | 33% |
| Injection, solution | 11 | 11.7% |
| Tablet, film coated, extended release | 10 | 10.6% |
| Tablet, extended release | 9 | 9.6% |
| Liquid | 7 | 7.4% |
| Injection | 5 | 5.3% |
| Aerosol, metered | 4 | 4.3% |
| Powder, for suspension | 3 | 3.2% |
| Tablet | 3 | 3.2% |
| Capsule | 2 | 2.1% |
| Granule | 2 | 2.1% |
| Aerosol | 2 | 2.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Kinase Inhibitor | 12 |
| Atypical Antipsychotic | 9 |
| Sodium-Glucose Cotransporter 2 Inhibitor | 7 |
| beta2-Adrenergic Agonist | 6 |
| Biguanide | 5 |
| Corticosteroid | 5 |
| Poly(ADP-Ribose) Polymerase Inhibitor | 4 |
| HMG-CoA Reductase Inhibitor | 4 |
| Interleukin-5 Receptor alpha-directed Cytolytic Antibody | 3 |
| Anticholinergic | 3 |
| Cholinergic Muscarinic Antagonist | 3 |
| Programmed Death Ligand-1 Blocker | 2 |
| CTLA-4-directed Blocking Antibody | 2 |
| GLP-1 Receptor Agonist | 2 |
| Antisense Oligonucleotide | 2 |
| Transthyretin-directed RNA Interaction | 2 |
| Phosphodiesterase 4 Inhibitor | 2 |
| Amylin Analog | 2 |
| Type I Interferon Receptor Antagonist | 2 |
| Estrogen Receptor Antagonist | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Etcamah | 0310-0075 | Tablet, film coated | New drug applications (NDA) | September 4, 2026 |
| Rilvegostomig | 0310-9700 | Liquid | Bulk ingredients | September 2, 2026 |
| Oleclumab | 0310-4141 | Liquid | Bulk ingredients | August 12, 2026 |
| Monalizumab | 0310-3333 | Liquid | Bulk ingredients | July 13, 2026 |
| Baxfendy | 0310-6002 | Tablet, film coated | New drug applications (NDA) | May 15, 2026 |
| Baxfendy | 0310-6001 | Tablet, film coated | New drug applications (NDA) | May 15, 2026 |
| Wainua | 0310-9420 | Injection, solution | New drug applications (NDA) | April 30, 2026 |
| Breztri | 0310-6616 | Aerosol, metered | New drug applications (NDA) | April 27, 2026 |
| Saphnelo | 0310-3080 | Injection, solution | Biologics (BLA) | April 24, 2026 |
| Tozorakimab | 0310-2021 | Liquid | Bulk ingredients | April 16, 2026 |
| Koselugo | 0310-0640 | Granule | New drug applications (NDA) | September 10, 2025 |
| Koselugo | 0310-0635 | Granule | New drug applications (NDA) | September 10, 2025 |
| Fasenra | 0310-1745 | Injection, solution | Biologics (BLA) | April 5, 2024 |
| Wainua | 0310-9400 | Injection, solution | New drug applications (NDA) | December 21, 2023 |
| Truqap | 0310-9501 | Tablet, film coated | New drug applications (NDA) | November 16, 2023 |
| Truqap | 0310-9500 | Tablet, film coated | New drug applications (NDA) | November 16, 2023 |
| Airsupra | 0310-9080 | Aerosol, metered | New drug applications (NDA) | October 2, 2023 |
| Imjudo | 0310-4535 | Injection, solution | Biologics (BLA) | October 21, 2022 |
| Imjudo | 0310-4505 | Injection, solution | Biologics (BLA) | October 21, 2022 |
| Micronized glycopyrronium bromide | 0310-0561 | Powder | Bulk ingredients | September 20, 2022 |
| Acalabrutinib | 0310-5512 | Tablet, film coated | Drugs for further processing | August 4, 2022 |
| Calquence | 0310-4513 | Tablet, film coated | New drug applications (NDA) | August 4, 2022 |
| Calquence | 0310-3512 | Tablet, film coated | New drug applications (NDA) | August 4, 2022 |
| Andexxa | 0310-3200 | Injection, powder, lyophilized, for solution | Biologics (BLA) | July 12, 2022 |
| Dapagliflozin | 0310-8210 | Tablet, film coated | Drugs for further processing | May 19, 2022 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.